Q3 FY2026 · ended Sep 30, 2026 · Revenue $24.40B, +38.6% YoY · Filed Oct 29, 2026
Eli Lilly And Company (LLY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $24.4 billion and net income of $6.5 billion. As of Sep 30, 2026 it held $8.9 billion in cash and investments and $47.0 billion in total debt.
Revenue
$24.40B
+38.6% vs year-ago quarter
Net income
$6.45B
+15.5% vs year-ago quarter
Operating cash flow
$11.40B
+29.0% vs year-ago quarter
Free cash flow
—
EPS
$7.22
+16.3% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
940.75M
-0.5% vs year-ago quarter
Net cash
$-38.09B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LLY (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- IN
- Headquarters
- Indianapolis, IN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 59478
- Former names
- LILLY ELI & CO (until Oct 25, 2019); LILLY ELI & CO ET AL (until Oct 14, 1994)
Other Pharmaceutical Preparations companies
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $24.4B | $23.0B | $19.8B | $19.3B | $17.6B |
| Net income | $6.5B | $7.1B | $7.4B | $6.6B | $5.6B |
| Diluted EPS | $7.22 | $7.94 | $8.26 | $7.39 | $6.21 |
| Operating cash flow | $11.4B | $10.7B | $5.3B | $3.2B | $8.8B |
| Total assets | $148.1B | $142.3B | $116.6B | $112.5B | $114.9B |
| Stockholders' equity | $40.3B | $33.9B | $31.2B | $26.5B | $23.8B |
| Cash and investments | $8.9B | $12.8B | $8.4B | $10.1B | $12.7B |
| Total debt | $47.0B | $47.9B | $39.4B | $43.9B | $40.9B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Other events
|
May 20, 2026 | May 20, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 7, 2026 | May 4, 2026 |
All 1001 Eli Lilly And Company SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.